Last reviewed · How we verify
NRT6003 Injection
NRT6003 is a radiopharmaceutical injection designed to deliver targeted radiation therapy to cancer cells.
NRT6003 is a radiopharmaceutical injection designed to deliver targeted radiation therapy to cancer cells. Used for Cancer (specific indication not publicly disclosed).
At a glance
| Generic name | NRT6003 Injection |
|---|---|
| Also known as | Yttrium-90 carbon microspheres |
| Sponsor | Chengdu New Radiomedicine Technology Co. LTD. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a radiomedicine product from Chengdu New Radiomedicine Technology Co. LTD., NRT6003 likely functions as a theranostic or therapeutic radiopharmaceutical that combines a radionuclide with a targeting vector to deliver localized radiation to tumor tissue while minimizing systemic exposure. The specific mechanism depends on the radionuclide used and the targeting moiety, which are not publicly disclosed in available sources.
Approved indications
- Cancer (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma (PHASE1)
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere (PHASE3)
- SIRT Versus cTACE for Unresectable HCC (CHANCE2506) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRT6003 Injection CI brief — competitive landscape report
- NRT6003 Injection updates RSS · CI watch RSS
- Chengdu New Radiomedicine Technology Co. LTD. portfolio CI